正在加载视频...

视频加载失败

Where does your proprietary data go once AI agents start touching it? Yorke Ξ Rhodes III 🟧 🇺🇦, Director Digital Transformation, Traceability & Co-Founder of Blockchain at Microsoft, describes a realization spreading through the enterprise space, and what it means for anyone with a proprietary way of doing business.

41,619 次观看 • 1 个月前 •via X (Twitter)

0 条评论

暂无评论

原始帖子的评论将显示在这里

相关视频

Big pharma just handed the AI industry one of the most important reality checks of 2026 (Save this). david friedberg revealed that Anthropic approached major life sciences companies with a pitch, share your proprietary data, sign an NDA and we will give you early access to a specialized life sciences model and nearly every company they spoke with said no. Here is what these pharma companies understood that many enterprises still have not. A large pharmaceutical company may have spent decades and tens of billions of dollars generating proprietary datasets, clinical trial results, genomic sequences, drug interaction data, compound libraries. That data is the business and the competitive moat that separates them from every other player in the industry lives in those datasets. Handing it to an AI lab in exchange for early access to a model is essentially handing your most valuable asset to a company whose entire business model depends on combining your data with everyone else's and then selling the output back to you and to your competitors. Palantir CEO Alex Karp made this exact point that enterprise leaders are paying for AI tokens that generate no tangible business value while simultaneously surrendering their most sensitive operational data to external providers. He called this transferring a company's alpha, the unique advantage that secures the business directly to a third-party lab. Microsoft CEO Satya Nadella echoed the same concern independently, warning that entire sectors might find their accumulated knowledge commoditized if they do not build their own data and model ownership layers. The structural problem is not unique to pharma but it applies to every enterprise sector. Every time an employee runs a query through a third-party frontier model, proprietary workflows, customer data, and strategic processes pass through infrastructure the enterprise does not control. The data already shows the market moving, Open-source captured 67% of all AI tokens processed in the first half of 2026, up from a fraction of that just twelve months earlier. The performance gap between proprietary frontier models and open-source alternatives has nearly closed, DeepSeek costs approximately 1/36th of GPT-5 for comparable workloads. What pharma figured out and what enterprises across every sector are starting to realize is that the model is not the moat but the data is. And once you hand your data to a model company, you have permanently surrendered the asset that took you decades and billions of dollars to build.

Milk Road AI

16,317 次观看 • 2 个月前